Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Changchun High-Tech Industries (Group) Inc. (000661.SZ)
CNY72.05
+0.45 (+0.63%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Torch Building 130021
Changchun, CN
Changchun, CN
CEO
Lei Jin
Website
cchn.com.cn
IPO
1996-12-18
ISIN CNE0000007J8
Description
Changchun High-Tech Industries (Group) Inc., operating with its various subsidiaries, is primarily involved in the production and distribution of biopharmaceutical products and traditional Chinese medicines across the Chinese market. Additionally, the company diversifies its activities into property development, real estate management, and leasing services. Founded in Changchun, China, in 1993, this enterprise was previously known as Changchun High & New Technology Industry (Group) Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY72.05
+0.45 (+0.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.43
Float Shares
282.74M
Free Float %
69.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.78% | -9.05% | -13.91% | -23.18% | -25.88% | -20.51% | -29.65% | -54.30% | -82.08% | +66.41% | +2,156.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
72.05
DCF (Unlevered)
143.84
+99.6%
DCF (Levered)
63.18
-12.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.80
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-10.3% Q1'26: -13.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-93.9% Q1'26: -41.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.4% Q1'26: +25.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.4% Q1'26: +13.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.1% Q1'26: +4.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.48× ★ Q1'26: 1.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.40B
est: 2.41B (-0.1%)
|
2.90B
est: 2.91B (-0.5%)
|
4.10B
est: 3.70B (+10.8%)
|
5.37B
est: 5.67B (-5.2%)
|
7.37B
est: 7.54B (-2.2%)
|
8.58B
est: 9.17B (-6.5%)
|
10.75B
est: 11.31B (-5.0%)
|
12.63B
est: 13.09B (-3.6%)
|
14.57B
est: 14.40B (+1.1%)
|
13.47B
est: 14.31B (-5.9%)
|
12.08B
est: 14.09B (-14.2%)
|
11.43B
10.30B – 12.12B
-18.8% YoY
|
12.41B
10.58B – 14.86B
+8.5% YoY
|
13.74B
12.01B – 15.58B
+10.7% YoY
|
| EBITDA |
686.96M
est: 989.85M (-30.6%)
|
858.83M
est: 1.20B (-28.4%)
|
1.19B
est: 1.52B (-21.7%)
|
1.79B
est: 2.33B (-23.4%)
|
2.91B
est: 3.10B (-6.3%)
|
3.95B
est: 3.77B (+4.6%)
|
4.86B
est: 4.65B (+4.4%)
|
5.32B
est: 5.39B (-1.2%)
|
6.14B
est: 5.93B (+3.6%)
|
4.07B
est: 4.76B (-14.6%)
|
804.49M
est: 4.69B (-82.8%)
|
3.81B
3.43B – 4.03B
-18.8% YoY
|
4.13B
3.52B – 4.94B
+8.5% YoY
|
4.57B
4.00B – 5.18B
+10.7% YoY
|
| EBIT |
610.26M
est: 916.58M (-33.4%)
|
776.97M
est: 1.11B (-30.0%)
|
1.11B
est: 1.41B (-21.4%)
|
1.68B
est: 2.16B (-22.0%)
|
2.77B
est: 2.87B (-3.7%)
|
3.77B
est: 3.49B (+8.0%)
|
4.58B
est: 4.31B (+6.3%)
|
4.94B
est: 4.99B (-1.0%)
|
5.65B
est: 5.49B (+2.9%)
|
3.50B
est: 4.20B (-16.7%)
|
43.73M
est: 4.14B (-98.9%)
|
3.36B
3.03B – 3.56B
-18.8% YoY
|
3.65B
3.11B – 4.37B
+8.5% YoY
|
4.04B
3.53B – 4.58B
+10.7% YoY
|
| Net Income |
384.48M
est: 510.11M (-24.6%)
|
484.85M
est: 578.12M (-16.1%)
|
661.95M
est: 772.76M (-14.3%)
|
1.01B
est: 1.16B (-12.9%)
|
1.78B
est: 1.69B (+5.3%)
|
3.05B
est: 2.98B (+2.4%)
|
3.76B
est: 4.10B (-8.3%)
|
4.14B
est: 4.41B (-6.1%)
|
4.53B
est: 4.74B (-4.3%)
|
2.58B
est: 3.87B (-33.3%)
|
154.97M
est: 2.11B (-92.7%)
|
1.12B
1.01B – 1.19B
-46.8% YoY
|
1.32B
947.65M – 2.18B
+18.1% YoY
|
1.62B
1.36B – 1.90B
+22.4% YoY
|
| SGA |
1.16B
est: 877.73M (+31.7%)
|
1.39B
est: 1.06B (+31.2%)
|
1.86B
est: 1.35B (+37.5%)
|
2.45B
est: 2.07B (+18.2%)
|
2.98B
est: 2.75B (+8.3%)
|
3.06B
est: 3.35B (-8.5%)
|
3.70B
est: 4.13B (-10.4%)
|
4.63B
est: 4.78B (-3.1%)
|
4.93B
est: 5.26B (-6.3%)
|
5.64B
est: 5.11B (+10.3%)
|
3.85B
est: 5.03B (-23.5%)
|
4.09B
3.68B – 4.33B
-18.8% YoY
|
4.43B
3.78B – 5.31B
+8.5% YoY
|
4.91B
4.29B – 5.57B
+10.7% YoY
|
| EPS |
1.47
est: 1.27 (+15.9%)
|
1.54
est: 1.44 (+7.2%)
|
1.95
est: 1.92 (+1.5%)
|
2.96
est: 2.87 (+3.0%)
|
5.14
est: 4.19 (+22.7%)
|
7.53
est: 7.40 (+1.8%)
|
9.30
est: 10.19 (-8.7%)
|
10.29
est: 10.96 (-6.1%)
|
11.21
est: 11.77 (-4.8%)
|
6.42
est: 9.64 (-33.4%)
|
0.39
est: 5.25 (-92.6%)
|
2.79
2.52 – 2.95
-46.8% YoY
|
3.30
2.36 – 5.43
+18.1% YoY
|
4.04
3.38 – 4.74
+22.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-495.70M
OE per share TTM
-1.23
Owner's Yield
-1.69%
Maintenance CapEx ratio
234.86%
Maint CapEx / Avg PPE
51.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 122 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 0.72% | 569.4K | 0.79% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.22% | 78.9K | 0.65% |
| 3 | HSBC MSCI China A UCITS ETF HMCT.L | 0.11% | 147.4K | 0.30% |
| 4 | Samsung KODEX China CSI300 ETF 283580.KS | 0.10% | 197.4K | 0.12% |
| 5 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.07% | 11.5K | 0.65% |
| 6 | iShares MSCI China A ETF CNYA | 0.06% | 147.6K | 0.60% |
| 7 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.06% | 78.7K | 0.35% |
| 8 | iShares MSCI China A UCITS ETF CNYE.MI | 0.06% | 56.3K | 0.45% |
| 9 | iShares MSCI China A UCITS ETF CNYA.L | 0.06% | 1.71M | 0.40% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.05% | 73.5K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.8K
Shares Outstanding
407.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing Jie | Deputy General Manager | — | male |
| Hong Yu Li | Board Secretary | — | male |
| Lei Jin | GM & Director | — | — |
| Peng Ye | Deputy General Manager | — | male |
| Xing Gong Zhu | Deputy GM & Chief Financial Officer | — | male |
| Xiufeng Li | Deputy GM & Director | — | male |
| Yan Zhang | Deputy General Manager | — | male |
| Zhigang Wang | Deputy GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000661.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
